Skip to main content
Contact Us
Subscribe
E-Edition
81°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AnaptysBio, Inc. - Common Stock
(NQ:
ANAB
)
26.10
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 11:12 AM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AnaptysBio, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
June 04, 2025
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via
Benzinga
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
June 04, 2025
Via
Benzinga
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
June 04, 2025
Via
Benzinga
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering
June 03, 2025
The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects.
Via
Stocktwits
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
June 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
May 28, 2025
Via
Benzinga
Where AnaptysBio Stands With Analysts
March 04, 2025
Via
Benzinga
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
May 28, 2025
Via
Benzinga
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
May 27, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Forecasting The Future: 6 Analyst Projections For AnaptysBio
May 06, 2025
Via
Benzinga
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
May 05, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Analyst Expectations For AnaptysBio's Future
February 04, 2025
Via
Benzinga
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From
Bright Peak Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Gains 1%; US Composite PMI Surges In March
March 24, 2025
Via
Benzinga
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
March 24, 2025
Via
Benzinga
Anaptys Announces Stock Repurchase Plan
March 24, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 13, 2025
Via
Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
March 13, 2025
Via
Benzinga
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in March Investor Conferences
February 27, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
February 12, 2025
Via
Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
February 12, 2025
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
Via
Investor's Business Daily
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
February 12, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 12, 2025
Via
Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
February 12, 2025
Via
Benzinga
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
February 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
February 03, 2025
From
AnaptysBio, Inc.
Via
GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 22, 2025
Via
Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
January 22, 2025
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.